Geoffrey Parsons, PhD

Geoffrey joined Ring in 2022 and now serves as Senior Vice President, Head of Research. He has more than 20 years of experience in the biotech and pharmaceutical industry, with deep expertise in the field of gene therapy and molecular biology. Geoffrey joined Ring from Bluebird Bio, where he led the Molecular and Vector Biology team, designing, producing, and testing therapeutic vectors for rare blood disorders and cancer immunotherapy. While at Bluebird he contributed to multiple FDA approvals, including Abecma, the first CAR-T cell therapy for relapsed or refractory multiple myeloma; Zynteglo, the first gene therapy approved for the treatment of transfusion-dependent thalassemia; and Skysona, a gene therapy for the treatment of adrenoleukodystrophy. Prior to Bluebird Bio, Geoffrey led various initiatives in the gene therapy group at Genzyme/Sanofi, where he worked with several different viral vector platforms and initiated multiple gene therapy applications within metabolic disease, neurodegeneration, and lysosomal storage disease.

Geoffrey received his BA in Molecular Biology and Biochemistry from Wesleyan University and his PhD from the University of California San Fransisco.